BioSpace News Archive

Gradalis, Inc. today announced that Steven Engle, Chief Executive Officer, will participate in a fireside chat at the Cantor Fitzgerald Future of Oncology Symposium, being held virtually from April 3 – 5, 2023.

Alpha Tau Medical Ltd., the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced that Raphi Levy, Chief Financial Officer, will present in-person at the Jefferies Radiopharma Innovation Summit in New York City on Monday, April 3rd, 2023.

Dyadic International, Inc. announced its financial results for year end 2022 and highlighted recent Company progress.

Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical”) today announced financial results and recent corporate highlights for the fourth quarter and full year ended December 31, 2022.

Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today reported business highlights and financial results for the fourth quarter and year ended December 31, 2022.

Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics and cell therapies intended to enhance function of Regulatory T Cells (Tregs) function, today announced its financial results for fiscal year ended December 31, 2022, and provided a clinical and business update.

Seer Inc., a life sciences company commercializing a disruptive new platform for proteomics, announced a new scientific publication in PLOS One demonstrating the unmatched utility of the Proteograph Product Suite to uncover novel insights in human health and disease with deep, unbiased proteomics.

The Lupus Research Alliance announced the Lupus Accelerating Breakthroughs Consortium, a first-of-its-kind public-private partnership bringing people with lupus together in collaboration with the U.S. FDA, other federal agencies, medical societies, industry, academic clinical researchers and scientists to overcome scientific hurdles that are beyond the capacity of any single entity and to advance the development of urgently needed, personalized treatments for lupus.

Sorrento Therapeutics, Inc. (OTC: SRNEQ, “Sorrento”) today announced that the U.S. Bankruptcy Court for the Southern District of Texas granted final approval of Sorrento’s $75 million debtor-in-possession (DIP) financing from JMB Capital Partners, in connection with Sorrento’s chapter 11 case that was filed on February 13, 2023.

PathoVax LLC (“PathoVax”) today announced that the U.S. Food and Drug Administration (FDA) has completed its review of the investigational new drug (IND) application for its licensed monovalent component- HPV16 RG1-VLP and concluded that a Phase 1 clinical trial in the United States and Austria is now given the go-ahead to proceed.